Ozanimod for Crohn's Disease

Recruiting in Palo Alto (17 mi)

+1276 other locations

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Celgene

Pivotal Trial (Near Approval)

Prior Safety Data

Approved in 2 jurisdictions

Trial Summary

What is the purpose of this trial?This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Eligibility Criteria

This trial is for people with moderately to severely active Crohn's Disease who have tried other treatments that didn't work. It's not for those with ulcerative colitis or conditions that might exclude them from safely participating.

Inclusion Criteria

I have been diagnosed with Crohn's disease.

I have tried a treatment for Crohn's disease that didn't work.

I do not have ulcerative colitis.

Participant Groups

The study tests ozanimod, an oral medication, as a maintenance therapy against a placebo (a pill without the active drug) to see if it helps keep Crohn's Disease under control.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: OzanimodExperimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention

Ozanimod is already approved in European Union, United States for the following indications:

🇪🇺 Approved in European Union as Ozanimod for: